Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s Hisun Gets Capreomycin WHO Prequalification

This article was originally published in PharmAsia News

Executive Summary

Hisun’s pre-qualification approval for capreomycin to treat second-line active tuberculosis cases may help bring costs down for a drug increasingly in demand as multi-drug resistant patients multiply worldwide.

You may also be interested in...



Lifestyle Disease Trend Continues In Asia - WHO Epidemiology Report

HONG KONG - Growing economies, improved diets and access to healthcare are having a positive effect on health across Asia, but the incidence of infectious diseases remains stubbornly high and the impact is compounded by rises in non-communicable lifestyle diseases. The latest set of statistical data from the World Health Organization suggests more and more countries are forced to tackle both simultaneously, and global and local pharma companies are racing to fill unmet needs

Lilly And China's Hisun Complete Technology Transfer For Antibiotic Capreomycin For TB

SHANGHAI - Eli Lilly and Chinese active pharmaceutical ingredient provider Hisun recently announced the completion of a technology transfer under which Lilly transferred technology to Hisun to produce finished products and API of its tuberculosis drug capreomycin

A Runaway Hit In US, Pfizer Gains EU Nod for Vyndaqel In Cardiomyopathy

Vydaqel saw its uptake take off in the US last year. UK’s NICE to pass judgement on cost effectiveness by June.

Topics

Related Companies

UsernamePublicRestriction

Register

SC087395

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel